Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics
Tharimmune, Inc. (NASDAQ:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today ...